ORIC Pharmaceuticals Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
86
- Stock Symbol
-
ORIC
- Share Price
-
$4.49
- (As of Monday Closing)
ORIC Pharmaceuticals General Information
Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 240 East Grand Avenue
- 2nd Floor
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
ORIC Pharmaceuticals Timeline
ORIC Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.49 | $4.56 | $2.36 - $7.48 | $202M | 39.6M | 1.05M | -$2.25 |
ORIC Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 73,750 | 73,750 | 291,192 | 1,018,213 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (90,767) | (90,767) | (77,956) | (73,009) |
| Net Income | (89,122) | (89,122) | (78,715) | (73,703) |
| Total Assets | 247,178 | 247,178 | 298,642 | 298,997 |
| Total Debt | 2,659 | 2,659 | 1,926 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ORIC Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ORIC Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ORIC Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to count
Drug Discovery
South San Francisco, CA
86
As of 2022
00000
000000000
00000
000000
ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000000
Hampton, NJ
000
As of 0000
00000
00000000
00000
000000
it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
0000000000000
San Diego, CA
000
As of 0000
00000
0000000000.
Add Comparison
ORIC Pharmaceuticals Competitors (82)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celldex Therapeutics | Formerly VC-backed | Hampton, NJ | 000 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. | |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 00000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 0000 0000000000000 | Formerly VC-backed | Redwood City, CA | 00 | 00000 | 00000000 | 00000 |
ORIC Pharmaceuticals Patents
ORIC Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4051688-A1 | Cd73 inhibitors | Pending | 30-Oct-2019 | 000000000 | |
| CA-3159248-A1 | Cd73 inhibitors | Pending | 30-Oct-2019 | 000000000 | |
| US-11530236-B2 | Cd73 inhibitors | Active | 30-Oct-2019 | 000000000 | 00 |
| US-20210214387-A1 | Cd73 inhibitors | Active | 30-Oct-2019 | 000000000 | |
| US-11028120-B2 | Cd73 inhibitors | Active | 30-Oct-2019 | C07H19/23 |
ORIC Pharmaceuticals Executive Team (16)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jacob Chacko MD | Chief Executive Officer & Board Member | ||
| Dominic Piscitelli | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| Charles Sawyers MD | Founder & Scientific Advisory Board | ||
| Richard Heyman Ph.D | Co-Founder, Chairman & Scientific Advisory Board Member | ||
| Scott Lowe Ph.D | Co-Founder & Scientific Advisory Board Member |
ORIC Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Angie You | ORIC Pharmaceuticals | Board Member | 000 0000 |
| Jacob Chacko MD | ORIC Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
| Laurence Lasky Ph.D | Self | Board Member | 000 0000 |
| Lori Kunkel MD | Self | Board Member | 000 0000 |
| Mardi Dier | ORIC Pharmaceuticals | Board Member | 000 0000 |
ORIC Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ORIC Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ORIC Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
38.65 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 455
Rank
00.00
Percentile
